Professor Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust and Professor of Cardiology at the National Heart and Lung Institute within Imperial College London. She is a British Heart Foundation intermediate clinical research fellow and clinical trialist with expertise in stable coronary artery disease, coronary intervention, invasive physiology and invasive intravascular imaging.

She leads a research group with a focus on clinical trials that impact the care of patients with cardiovascular disease. She believes in rigorous testing of clinical practice and the use of evidence-based medicine in all aspects of medical care.

She designed and led the only placebo-controlled trials of coronary angioplasty, ORBITA and ORBITA-2, published in The Lancet and the New England Journal of Medicine respectively. She was also the chief investigator of the ORBITA-COSMIC trial, published in The Lancet, and ORBITA-STAR, published in JACC. She led The Lancet commission on atherosclerotic heart disease. She is currently leading the ORBITA-FIRE, ORBITA-MOON and ORBITA-SOLAR trials and has over 160 peer-reviewed publications and a h-index of 44. She is actively involved in the development and recruitment for many multi-centre international clinical trials.

 She is a deputy editor at JACC. She is Deputy Director and head of the second year of Medicine at Imperial College London. She is co-head of the cardiovascular theme of the Imperial NIHR Biomedical Research Centre.

Publications